Skip to Content

McKesson Corp - Stock Quote MCK

Rating as of

Morningstar's McKesson Corp Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Another Strong Quarter for Narrow-Moat McKesson; Opioid Litigation Case Settled in 48 States

Dylan Finley, CFA Equity Analyst

Analyst Note

| Dylan Finley, CFA |

Overall, we are pleased with McKesson's fiscal fourth-quarter results. We anticipate a raise in our fair value estimate following a more thorough review of the company's results and 2023 guidance. However, our current take is that the company's strong market performance over the past several months (shares have climbed 35% year to date) has placed the stock in overvalued territory. 

Read Full Analysis

McKesson Corp's Company Profile

Business Description

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

6555 State Highway 161
Irving, TX, 75039
T +1 972 446-4800
Sector Healthcare
Industry Medical Distribution
Most Recent Earnings Mar 31, 2022
Fiscal Year End Mar 31, 2023
Stock Type Classic Growth
Employees 75,000

McKesson Corp's Related Articles & News